FDA approves Amgen's sBLA for Vectibix in mCRC

Amgen Inc. (NASDAQ:AMGN) said FDA approved an sBLA for Vectibix panitumumab to treat wild-type Ras metastatic colorectal cancer (mCRC), defined as wild-type in both K-Ras (KRAS) and neuroblastoma Ras viral (v-Ras) oncogene (NRAS) as determined by an FDA-approved test. It is indicated as first-line therapy with FOLFOX chemotherapy and monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin and irinotecan-containing chemotherapy.

The therapy was previously approved to treat wild-type KRAS mCRC...